Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | ESR1 | P03372 | 4/20 | 0.50 |
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21203258 | 0.88 | LTA4H (0.60) | KDM4EALDH1A1POLBGAAESR1 | |
| SCHEMBL10021700 | 0.87 | MAOB (0.59) | KDM4EPOLBGAAESR1MAOB | |
| SCHEMBL15996545 | 0.86 | MAOB (0.51) | KDM4EALDH1A1SMN1; SMN2POLBGAA | |
| SCHEMBL15996357 | 0.83 | KDM4E (0.58) | KDM4EALDH1A1SMN1; SMN2POLBGAA | |
| SCHEMBL21203260 | 0.83 | MAOB (0.60) | KDM4EALDH1A1SMN1; SMN2ESR1MAOB | |
| SCHEMBL10021699 | 0.82 | MAOB (0.60) | KDM4EALDH1A1SMN1; SMN2MAOBKMT2A | |
| SCHEMBL13766268 | 0.82 | KDM4E (0.97) | KDM4EALDH1A1SMN1; SMN2POLBGAA | |
| SCHEMBL14970709 | 0.82 | KDM4E (0.97) | KDM4EALDH1A1SMN1; SMN2POLBGAA | |
| Hydrochloric Acid SCHEMBL14966569 | 0.81 | KDM4E (0.94) | KDM4EALDH1A1SMN1; SMN2POLBGAA | |
| SCHEMBL305458 | 0.80 | KDM4E (1.00) | KDM4EALDH1A1SMN1; SMN2ESR1BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9359279-B2 | Treatment of cancer, inflammatory disease, and autoimmune disease | ALLIANZ PHARMASCIENCE LTD. (TW) | 2016-06-07 | — | — | US | disclosed |
| US-20140371177-A1 | TREATMENT OF CANCER, INFLAMMATORY DISEASE, AND AUTOIMMUNE DISEASE | ALLIANZ PHARMASCIENCE LTD. (TW) | 2014-12-18 | — | — | US | disclosed |
| US-8822732-B2 | 1,5-diphenyl-penta-1,4-dien-3-one compounds | ANDROSCIENCE CORPORATION (US) | 2014-09-02 | — | — | US | disclosed |
| US-20120046247-A1 | 1,5-DIPHENYL-PENTA-1,4-DIEN-3-ONE COMPOUNDS | ALLIANZ PHARMASCIENCE LTD. (TW) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046247-A1 | 1,5-DIPHENYL-PENTA-1,4-DIEN-3-ONE COMPOUNDS | PDCD5, IL5, MALT1 | KDM4E 1325/4885ALDH1A1 67/4885SMN1; SMN2 3326/4885 |
| US-20140371177-A1 | TREATMENT OF CANCER, INFLAMMATORY DISEASE, AND AUTOIMMUNE DISEASE | PHOSPHO1, SELENOI, CD2 | KDM4E 433/4885ALDH1A1 959/4885SMN1; SMN2 3051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.